Magazine Article | September 3, 2018

Companies To Watch: United Neuroscience

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader
Follow Me On Twitter @WayneKoberstein

Novel peptide-based vaccines to prevent and treat neurological diseases

SNAPSHOT

United Neuroscience (UNS) is developing vaccines to stimulate the body’s production of “endobodies” against beta-amyloid plaque in Alzheimer’s disease and proteins with causative roles in other diseases. The company engineers its “endobody vaccines” to overcome the body’s natural resistance to mounting immune attacks against endogenous proteins, as traditional vaccines do against foreign pathogens. Its Alzheimer’s vaccine UB-311 is now in Phase 2 clinical trials, and another vaccine, UB-312, is entering clinical trials. A third product, a vaccine targeting tau protein in Alzheimer’s, is in preclinical research. In the preclinical stages are other candidates targeting disease-related neuropeptides and cytokines to treat migraine and several neuroinflammatory indications, neuropathic pain, and neuromuscular dystrophies.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Life Science Leader